<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02740361</url>
  </required_header>
  <id_info>
    <org_study_id>IDEMS</org_study_id>
    <secondary_id>RG-1507-05418</secondary_id>
    <nct_id>NCT02740361</nct_id>
  </id_info>
  <brief_title>Online Program to Reduce Depression in MS</brief_title>
  <official_title>International Deprexis Trial in Multiple Sclerosis (IDEMS) - a Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Multiple Sclerosis Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Missouri, Kansas City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Goettingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NeuroCure Clinical Research Center, Charite, Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international, multicenter, randomized controlled trial of an internet-based CBT
      intervention for depression (Deprexis) conducted in five MS centers in the US and Germany.
      The trial consists of a three-arm primary trial phase and an extension phase targeted at
      maintenance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depression is highly common in MS with a lifetime risk for major depressive disorder (MDD) as
      high as 25-50% and a 12-month prevalence of up to 25%, particularly in younger patients.
      Depression in MS has been linked to biological as well as psychological factors and
      substantially impacts psychosocial function. Importantly, depressive symptoms correlate with
      decreased quality of life, absence from work, and lower social support and are among the
      strongest predictors for suicidal ideation in MS patients.

      Despite its immediate clinical relevance, depression in MS remains underdiagnosed and often
      untreated and evidence for the efficacy of pharmacological or non-pharmacological
      interventions for MS-associated depression is scarce. For example, guidelines recently
      published by the AAN concluded that evidence for pharmacotherapy and individual or group
      therapies for MS-depression was insufficient but recommended cognitive behavioral therapy
      (CBT) delivered by phone with weak level of evidence. Such approaches, however, still require
      availability of a trained psychotherapist.

      Given the mobility problems, cognitive impairment, and fatigue typically associated with MS
      as well as the limited availability of psychotherapists, self-guided, automated,
      internet-based interventions may help to overcome treatment barriers often encountered by
      patients with MS. In a recent phase II randomized controlled trial (RCT) in Germany, the
      investigators found one such internet-based CBT program, Deprexis, to significantly reduce
      depressive symptoms in MS (Fischer et al., Lancet Psychiatry 2015). Despite these encouraging
      results, large, definitive trials of the most promising therapeutic approaches for
      MS-associated depression that could inform clinical practice are completely lacking.

      Here, the investigators conduct a large, international, multicenter RCT of the Deprexis
      program to treat depression in MS patients. Patients will be recruited in five specialized MS
      centers in Germany (Charité Berlin and University Medical Center Hamburg) and the US (Cedars
      Sinai Los Angeles, University of Missouri - Kansas City, and Penn State University). The
      investigators plan to enroll n=400 patients who will be randomly assigned to two different
      versions of Deprexis (either Deprexis alone or Deprexis plus regular Email support,
      DeprexisPlus) for 3 months or a waitlist control group and undergo clinical assessments at
      baseline and month 3. In addition, the investigators will conduct long-term online follow up
      at month 6 and month 12.

      The trial will address the following three main aims:

      Aim 1: To definitively test the effectiveness of Deprexis for reducing depressive symptoms in
      MS at the end of treatment.

      Aim 2: To determine the added value of email support for Deprexis (DeprexisPlus) in MS.

      Aim 3: To explore the long-term stability of therapeutic effects (12 months) and the
      potential of a booster session to enhance maintenance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Beck Depression Inventory-II</measure>
    <time_frame>Month 0 to Month 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>WHO Quality of Life scale (WHO-QOL BREF)</measure>
    <time_frame>Month 0 to Month 3</time_frame>
    <description>4 subscales (Physical, Psychological, Social Relationships, Environmental)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Impact Scale (MSIS)</measure>
    <time_frame>Month 0 to Month 3</time_frame>
    <description>2 subscales (Physical and Psychological)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Scale for Motor and Cognitive Functions (FSMC)</measure>
    <time_frame>Month 0 to Month 3</time_frame>
    <description>Total score and 2 subscales (Motor and Cognitive)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chalder Fatigue Scale</measure>
    <time_frame>Month 0 to Month 3</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)</measure>
    <time_frame>Month 0 to Month 3</time_frame>
    <description>Consists of 3 subtests. 1. SMDT (total score), CVLT-II (2 scores: learning score and delayed recall), and BVMT-R (2 scores: learning score and delayed recall)</description>
  </other_outcome>
  <other_outcome>
    <measure>Suicide Behaviors Questionnaire-Revised (SBQ-R)</measure>
    <time_frame>Month 3</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mini International Neuropsychiatric Interview, clinician rating, Version 5.0.0</measure>
    <time_frame>Month 0 to Month 3</time_frame>
    <description>Dichotomous variable &quot;Major Depressive Episode, Current (yes/no)&quot; according to module A of the MINI.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Deprexis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive access to the web-based Deprexis program, an online tool based on principles of cognitive behavioral therapy. Contents include (1) psychoeducation, (2) behavioral activation, (3) cognitive modification, (4) mindfulness and acceptance, (5) interpersonal skills, (6) relaxation, physical exercise and lifestyle modification, (7) problem solving, (8) expressive writing and forgiveness, (9) positive psychology, and (10) emotion-focused interventions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DeprexisPlus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive the web-based Deprexis program (see above) plus scheduled e-mail contact (1x/week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Waitlist Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants randomized to the control group will wait for access to the Deprexis program (waitlist control) for 6 months. After the 6-month waiting period, participants in this group will have full access to Deprexis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Deprexis, DeprexisPlus</intervention_name>
    <description>Online program Deprexis, either as a stand-alone internet-based intervention (Deprexis) or with added standardized email support by a clinical psychologist (DeprexisPlus). In this trial, we will use a Version of Deprexis that has been adapted to MS-specific needs.</description>
    <arm_group_label>Deprexis</arm_group_label>
    <arm_group_label>DeprexisPlus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  age &gt; 18

          -  neurologist-confirmed diagnosis of MS (all forms)

          -  self-reported depressive symptoms (BDI-Fastscreen &gt; 4)

          -  fluent in German or English (depending on study site),

          -  willingness to engage in self-administration of an iCBT intervention for 3 months and
             complete follow-up

          -  ability to travel to the outpatient center for two clinical assessments (baseline and
             month 3)

          -  internet access at home

        Exclusion criteria:

          -  unwilling or unable to consent,

          -  diagnosis of bipolar or psychosis (as determined by M.I.N.I structured interview),

          -  substantial neurocognitive impairments such as dementia or autism

          -  moderate or high risk of suicide (according to MINI module C) or by clinical
             impression

          -  very severe depression that would interfere with the ability to participate in the
             study (based on clinical judgment by the physician at the recruitment site).

          -  current psychotherapy/behavioral treatments for depression

          -  started pharmacotherapy for depression within the last 2 months

          -  MS relapse or steroid treatment in the last 4 weeks

          -  concurrent participation in another clinical trial that includes an intervention

          -  refusal to saving, processing and forwarding of pseudonymized data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan M Gold, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Charité University, Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Friedemann Paul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité University, Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christoph Heesen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nancy Sicotte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jared Bruce, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri, Kansas City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharon Lynch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri, Kansas City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Arnett, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rona Moss-Morris, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tim Friede, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Goettingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Björn Meyer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GAIA Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan M Gold, PhD</last_name>
    <phone>+49 450 517 594</phone>
    <email>stefan.gold@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph Heesen, MD</last_name>
    <email>heesen@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Sicotte, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nancy L Sicotte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Missouri, Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jared Bruce, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jared Bruce, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sharon Lynch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State University</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Arnett, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Peter Arnett, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité University</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Gold, PhD</last_name>
      <email>stefan.gold@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Friedemann Paul, MD</last_name>
      <email>friedemann.paul@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Friedemann Paul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Heesen, MD</last_name>
      <email>heesen@uke.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Heesen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fischer A, Schröder J, Vettorazzi E, Wolf OT, Pöttgen J, Lau S, Heesen C, Moritz S, Gold SM. An online programme to reduce depression in patients with multiple sclerosis: a randomised controlled trial. Lancet Psychiatry. 2015 Mar;2(3):217-23. doi: 10.1016/S2215-0366(14)00049-2. Epub 2015 Feb 25.</citation>
    <PMID>26359900</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Friedemann Paul</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual data on the primary endpoint will be published alongside the trial report in a peer reviewed journal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

